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Emilia-Romagna was one of the Italian regions mostly affected
by the COVID-19 pandemic, and lockdown measures were
taken to slow the COVID-19 outbreak.1,2,3 All routine activities
in Modena hospitals were suspended; however, urgent proce-
dures were still to be performed. Setting the priority of proce-
dures in oncological dermatology in the COVID-19 era is
challenging.4,5,6
We share our experience as a dermatological surgical unit at
the Policlinico of Modena, highlighting the resetting of priorities
and procedures, and the safety measures applied.
In 2019, 5483 surgical procedures were performed in our
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tumor
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Inflammatory
Suspicious blistering disease Punch biopsy for histology and direct immunofluorescence
Erythroderma Punch biopsy
All non-severe and not life-
threatening skin conditions Punch biopsy postponed
Figure 1 Reset of clinical priorities after the COVID-19 pandemic for dermatologic surgery planning. *SLB: sentinel node biopsy.
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Figure 2 Preoperative and operative procedures for hospital admission (inpatient and outpatient). PPE: personal protection equipment.
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outpatients. Weekly, our surgical activity consists of (i) four ses-
sions of major surgery for inpatient with anaesthesiologic sup-
port, 3 three patients/session; (ii) four day-surgery sessions, four
patients/session; (iii) 13 sessions of outpatient surgeries.
After lockdown (9 March 2020), dermatology departments
were challenged to a sudden reorganization of surgical activity
within 48 h. We had to perform only undelayable urgent inter-
ventions, leading to a new definition of priorities (Fig. 1). We
limited our activity to potentially life-threatening or severe can-
cer types, such as melanocytic lesions suspicious of thick mela-
noma, histologically confirmed thick melanoma, histologically
confirmed infiltrating high-risk squamous cell carcinoma (SCC)
according to NCCN guidelines7 and rapidly growing nodular
lesions. All clinical charts were reviewed to assign these new pri-
orities. We treated thick melanoma by performing both wide
excision and sentinel node biopsy, while wide excision for
already confirmed thin and in situ melanoma was deferred.
Recently, different approaches were proposed regarding the pos-
sibility to postpone the node biopsy.6,8,9
Regarding SCC, the excision was performed in line with cur-
rent guidelines while simple techniques, such as dermo-epider-
mal grafts, were selected for immediate reconstruction in order
to shorten the hospitalization period. For in situ SCC and basal
cell carcinoma (BCC), surgical treatment was postponed. Diag-
nostic incisional biopsies were restricted to severe diseases, such
as suspicious blistering diseases or erythroderma.
Moreover, we set a new weekly plan of surgical sessions, con-
sisting of (i) one session of major surgeries; (ii) two sessions of
day surgeries; (iii) two sessions for outpatient surgeries; (iv)
everyday, two urgent biopsies for in/outpatients.
All activities were performed wearing appropriate individual
protective devices, such as FFP2 or FFP3 masks covered with a
disposable surgical mask, protective eye-goggles or helmets, and
overshoes in addition to the standard surgical equipment. Sur-
geons were requested to wear surgical equipment in a clean and
safe area, different from the area they took off the equipment.
A strict triage procedure was applied before the admission of
patients (Fig. 2). Consecutive surgical activities for outpatients
were planned with a 45-min interval, to allow thorough cleaning
of the operation room.
Dermatological surgery is considered a low-/medium-risk
surgery. This also remains true in the current COVID-19 era,
but only when the patient can safely wear a mask. For proce-
dures on the face, we think that dermatological surgery should
be considered as a high-risk procedure. Therefore, we suggest
that independently from the type of anaesthesia used, it should
be mandatory to wear high protection mask (FFP3) during sur-
gery on the facial area. For body areas other than face, we suggest
that FFP2 can be considered as an appropriate protection device.
We also believe that standardized consent forms should be
prepared to inform patients of the inherent risk of getting
infected from SARS-CoV-2 while they are in the hospital, in an
effort to ensure transparency. Moreover, patients with dermato-
logical conditions may feel abandoned, given the relocation of
resources to address the pandemic emergency. It is therefore
crucial to maintain proper communication with patients, ensur-
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